Imatinib, Dasatinib, Nilotinib, Bosutinib
|
Chronic myelogenous leukemia
|
BCR-ABL1 fusion
|
Indication for therapy
|
Ponatinib
|
Chronic myelogenous leukemia
|
BCR-ABL1 fusion
|
Only indicated for T315I mutations
|
T315I resistance mutation
|
Erlotinib, Afatinib
|
Lung adenocarcinoma
|
EGFR
|
Indication for therapy
|
Exon 19 deletions
|
L858R
|
Vemurafenib, Dabrafenib
|
Melanoma
|
BRAF V600E
|
Indication for therapy
|
Tramatenib
|
Melanoma
|
BRAF V600E/K
|
Indication for therapy
|
Crizotinib
|
Lung cancer
|
ALK gene fusions
|
Indication for therapy
|
Cetuximab
|
Colon cancer
|
KRAS codon 12, 13
|
Contraindication to therapy
|
Olaparib
|
Ovarian cancer
|
BRCA1 and BRCA2 mutations
|
Indication for therapy
|